Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Direct oral anticoagulants (DOACs) have emerged as alternatives to vitamin K-antagonists (eg, warfarin) for the long-term management of stroke prevention for non-valvular atrial fibrillation or venous thromboembolic disease. Favourable side-effect profiles and absence of therapeutic monitoring are important benefits of these newer agents. Warfarin is readily reversed with fresh frozen plasma (FFP) or prothrombin complex concentrates.1 The first reversal agent for DOACs, idarucizumab recently received Food and Drug Administration approval as the reversal of the direct thrombin inhibitor, dabigatran. A reversal agent for the factor Xa-inhibitors, Andexanet Alfa is the subject of a recent Phase 3a trial and the core topic of this commentary.2
In a two-part, randomised, placebo-controlled study, healthy, older volunteers were established on 5 mg of apixaban twice daily or 20 mg of …
Contributors KG and IJW have contributed to the literature and writing of this manuscripts.
Competing interests KG is a Co-Investigator in a prospective, open-label study of Andexanet-Alfa in patients receiving factor Xa inhibitors with acute major bleeding, sponsored by Portola Pharmaceuticals (NCT02329327). IJW is the Principal Investigator in a prospective, open-label study of Andexanet Alfa in patients receiving factor Xa inhibitors with acute major bleeding, sponsored by Portola Pharmaceuticals (NCT02329327) and has recently received grant support from CSL Behring and Terumo BCT.
Provenance and peer review Commissioned; internally peer reviewed.